09/16/15 - 11:10 AM EDT
Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.
09/16/15 - 09:47 AM EDT
Amgen is acquiring a privately held company developing a cholesterol-lowering pill just weeks after receiving approval for its own cholesterol-lowering injection.
09/15/15 - 09:59 AM EDT
An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.
09/14/15 - 06:27 AM EDT
A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.
09/10/15 - 11:39 AM EDT
FDA missed a deadline earlier this week to finalize the Biomarin/Sarepta advisory panels on Nov. 23-24, if (and only if) Nov. 23-24 were the chosen dates.
09/10/15 - 11:00 AM EDT
Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.
09/09/15 - 09:24 AM EDT
Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.
09/09/15 - 01:01 AM EDT
The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.
09/08/15 - 04:41 PM EDT
Four biotech companies announced important clinical trials results Tuesday at market close.
09/08/15 - 12:12 PM EDT
Sell-side cheerleading on behalf of their employer's banking clients has become such a standard practice that anything remotely bearish is news.